Novartis Willful Patent Infringement Claims Dismissed In New York

(October 26, 2018, 12:56 PM EDT) -- NEW YORK — A New York federal judge on Oct. 24 found that allegations of willful infringement levied in connection with patented gene expression technology fail to state a claim (Novartis Vaccines and Diagnostics Inc. et al., v. Regeneron Pharmaceuticals Inc., No. 18-2434, S.D. N.Y., 2018 U.S. Dist. LEXIS 182600)....

Attached Documents

Related Sections